keyword
https://read.qxmd.com/read/38720531/evaluation-of-potential-drug-drug-interactions-with-medical-cannabis
#1
REVIEW
Jessie Jia Yi Ho, Chenyi Goh, Caitlin Shen Ai Leong, Khuen Yen Ng, Athirah Bakhtiar
Cannabis-drug interactions have caused significant concerns, mainly due to their role in the cytochrome P450 (CYP) enzyme-mediated metabolic pathway of numerous medications. A systematic review was conducted to gain an overview of the potential interactions of cannabis with different drug classes by extracting pertinent information from published study data. From the inception of the study to October 1, 2023, we performed a systematic search of PubMed, Scopus, clinicaltrials.gov, and Web of Science. We included 54 out of 464 articles, and a total of 20 drug classes were identified to have interactions with medicinal cannabis...
May 2024: Clinical and Translational Science
https://read.qxmd.com/read/38719969/evaluation-of-the-immune-system-status-and-hematological-dyscrasias-among-amphetamine-and-cannabis-abusers-at-eradah-hospital-in-qassim-saudi-arabia
#2
JOURNAL ARTICLE
Amal Hussain Mohammed, Atheer Saleh Aljarallah, Mohsina Huq, Amal M H Mackawy, Basmah F Alharbi, Khulud Salem Almutairi, Abdulmohsen M Alruwetei, Ahmad Abdulaziz A Almatroudi, Hajed Obaid Alharbi, Said Abdel Mohsen A Aljohery, Afshan Zeeshan Wasti
This cross-sectional study aims to evaluate the immune system status and hematological disturbances among individuals who abuse amphetamines and cannabis. Substance abuse, particularly of amphetamines and cannabis, has been associated with various adverse effects on the body, including potential impacts on the immune system and hematological parameters. However, limited research has been conducted to comprehensively assess these effects in a cross-sectional design. Additionally, fungal infections are on the rise internationally, and immune-compromised people are particularly susceptible...
May 8, 2024: Scientific Reports
https://read.qxmd.com/read/38717605/emerging-pharmacotherapy-for-the-treatment-of-cannabis-use-disorder
#3
REVIEW
Ahmad Shamabadi, Razman Arabzadeh Bahri, Hanie Karimi, Ehsan Heidari, Shahin Akhondzadeh
INTRODUCTION: About one-fifth of cannabis users, the most commonly used illicit substance, have cannabis use disorder (CUD). Psychiatric disorders and suicide are more common in these patients, and the disability-adjusted life years were reported to be 0.69 million. Pharmacotherapy for CUD is an unmet public health need, as current evidence-based therapies have limited efficacy. AREAS COVERED: After explaining the pathophysiology of CUD, the effects of emerging pharmacological interventions in its treatment obtained from randomized controlled trials were reviewed in light of mechanisms of action...
May 8, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38716117/differential-effects-of-cannabis-constituents-on-schizophrenia-related-psychosis-a-rationale-for-incorporating-cannabidiol-into-a-schizophrenia-therapeutic-regimen
#4
REVIEW
Kennadi Johnson, Abby J Weldon, Melissa A Burmeister
Schizophrenia is a serious mental health disorder that confers one of the highest mortality rates of all psychiatric illnesses. Although the disorder's psychotic symptoms are treatable with conventional antipsychotics, they remain incurable. Moreover, medication adherence is poor, and individuals with schizophrenia choose to self-medicate with illicit substances, including cannabis. It is well-established that the delta-9-tetrahydrocannabinol (delta-9-THC) component of cannabis elicits psychotomimetic effects at high doses; worsens schizophrenia-related psychosis; commonly develops into cannabis use disorder in individuals with schizophrenia; and increases the risk of earlier-onset schizophrenia symptoms in those harboring genetic susceptibility...
2024: Frontiers in Psychiatry
https://read.qxmd.com/read/38714200/medical-cannabis-in-psychiatry
#5
EDITORIAL
Kirsten R Müller-Vahl, Georg Juckel
No abstract text is available yet for this article.
May 2024: Pharmacopsychiatry
https://read.qxmd.com/read/38713939/cannabinoid-levels-description-in-a-cohort-of-patients-with-chronic-and-neuropathic-pain-treated-with-cannabis-decoction-a-possible-role-of-tdm
#6
JOURNAL ARTICLE
Alessandra Manca, Cristina Valz, Francesco Chiara, Jacopo Mula, Alice Palermiti, Martina Billi, Miriam Antonucci, Amedeo De Nicolò, Nicola Luxardo, Daniele Imperiale, Flavio Vischia, David De Cori, Jessica Cusato, Antonio D'Avolio
The phytocomplex of Cannabis is made up of approximately 500 substances: terpeno-phenols metabolites, including Δ-9-tetrahydrocannabinol and cannabidiol, exhibit pharmacological activity. Medical Cannabis has several pharmacological potential applications, in particular in the management of chronic and neuropathic pain. In the literature, a few data are available concerning cannabis pharmacokinetics, efficacy and safety. Thus, aim of the present study was the evaluation of cannabinoid pharmacokinetics in a cohort of patients, with chronic and neuropathic pain, treated with inhaled medical cannabis and decoction, as a galenic preparation...
May 6, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38708699/-not-available
#7
REVIEW
Mia Hovgaard Jessen, Merete Petersen, Peter Derek Christian Leutscher
In the last decade, patients with chronic pain have expressed increasing interest in cannabis-derived products for adjuvant therapy when treatment is deemed refractory to conventional analgesics. At present, clinical evidence to support this treatment approach appears to be sparse. Not because clinical studies as such are lacking, but rather as a result of methodological bias in relation to study design, patient populations, and treatment protocols. In this review, research in cannabis medicine for relief of chronic pain is reviewed, mainly with reference to published meta-analytic studies...
April 8, 2024: Ugeskrift for Laeger
https://read.qxmd.com/read/38708199/elemental-composition-of-commercially-available-cannabis-rolling-papers
#8
JOURNAL ARTICLE
Derek Wright, Michelle M Jarvie, Benjamin Southwell, Carmen Kincaid, Judy Westrick, S Sameera Perera, David Edwards, Robert B Cody
With the recent legalization of cannabis in multiple jurisdictions and widespread use as a medical treatment, there has been an increased focus on product safety and the potential impacts of contaminants on human health. One factor that has received little attention is the possible exposure to potentially hazardous levels of toxic elements from rolling (smoking) papers. The elemental composition of rolling papers is largely unregulated, with a minority of jurisdictions regulating papers only when they are part of a final cannabis product...
April 30, 2024: ACS Omega
https://read.qxmd.com/read/38702834/an-emerging-trend-in-novel-psychoactive-substances-npss-designer-thc
#9
REVIEW
Cristian Caprari, Elena Ferri, Maria Angela Vandelli, Cinzia Citti, Giuseppe Cannazza
Since its discovery as one of the main components of cannabis and its affinity towards the cannabinoid receptor CB1, serving as a means to exert its psychoactivity, Δ9 -tetrahydrocannabinol (Δ9 -THC) has inspired medicinal chemists throughout history to create more potent derivatives. Initially, the goal was to synthesize chemical probes for investigating the molecular mechanisms behind the pharmacology of Δ9 -THC and finding potential medical applications. The unintended consequence of this noble intent has been the proliferation of these compounds for recreational use...
May 3, 2024: Journal of cannabis research
https://read.qxmd.com/read/38700395/state-level-policies-and-receipt-of-cdc-informed-opioid-thresholds-among-commercially-insured-new-chronic-opioid-users
#10
JOURNAL ARTICLE
Martin J Calabrese, Fadia T Shaya, Francis Palumbo, Mary Lynn McPherson, Ester Villalonga-Olives, Zafar Zafari, Ryan Mutter
OBJECTIVES: To evaluate the association of state-level policies on receipt of opioid regimens informed by Centers for Disease Control and Prevention (CDC) morphine milligram equivalent (MME)/day recommendations. DESIGN: A retrospective cohort study of new chronic opioid users (NCOUs). SETTING: Commercially insured plans across the United States using IQVIA PharMetrics® Plus for Academics database with new chronic use between January 2014 and March 2015...
2024: Journal of Opioid Management
https://read.qxmd.com/read/38696245/using-large-language-models-to-support-content-analysis-a-case-study-of-chatgpt-for-adverse-event-detection
#11
JOURNAL ARTICLE
Eric C Leas, John W Ayers, Nimit Desai, Mark Dredze, Michael Hogarth, Davey M Smith
This study explores the potential of using large language models to assist content analysis by conducting a case study to identify adverse events (AEs) in social media posts. The case study compares ChatGPT's performance with human annotators' in detecting AEs associated with delta-8-tetrahydrocannabinol, a cannabis-derived product. Using the identical instructions given to human annotators, ChatGPT closely approximated human results, with a high degree of agreement noted: 94.4% (9436/10,000) for any AE detection (Fleiss κ=0...
May 2, 2024: Journal of Medical Internet Research
https://read.qxmd.com/read/38693590/medicinal-cannabis-medcan-3-a-randomised-multicentre-double-blind-placebo-controlled-trial-to-assess-thc-cbd-1-20-to-relieve-symptom-burden-in-patients-with-cancer-a-study-protocol-for-a-randomised-controlled-trial
#12
MULTICENTER STUDY
Taylan Gurgenci, Janet Hardy, Georgie Huggett, Karyn Foster, Anita Pelecanos, Ristan Greer, Jennifer Philip, Alison Haywood, Ruwani Mendis, Patsy Yates, Phillip Good
BACKGROUND: Distressing symptoms are common in advanced cancer. Medicinal cannabinoids are commonly prescribed for a variety of symptoms. There is little evidence to support their use for most indications in palliative care. This study aims to assess a 1:20 delta-9-tetrahydrocannabinol/cannabidiol (THC/CBD) cannabinoid preparation in the management of symptom distress in patients with advanced cancer undergoing palliative care. METHODS AND DESIGN: One hundred and fifty participants will be recruited across multiple sites in Queensland, Australia...
May 1, 2024: Trials
https://read.qxmd.com/read/38693376/-not-available
#13
REVIEW
Martin Storr
No abstract text is available yet for this article.
May 2024: MMW Fortschritte der Medizin
https://read.qxmd.com/read/38690624/cannabis-legalization-and-resource-use-for-ingestions-by-young-children
#14
JOURNAL ARTICLE
Patrick S Walsh, Amanda S Dupont, Matthew J Lipshaw, Alexis Visotcky, Danny G Thomas
OBJECTIVE: In conjunction with widening legalization, there has been a rapid rise in unintentional cannabis ingestions in young children. We sought to determine if the legal status of recreational cannabis was associated with resource use in young children with cannabis poisoning. METHODS: This retrospective cross-sectional study of the Pediatric Health Information System included emergency department encounters between January 2016 and April 2023 for children <6 years of age with a diagnosis indicating cannabis ingestion...
May 1, 2024: Pediatrics
https://read.qxmd.com/read/38690380/oral-health-status-among-recreational-cannabis-marijuana-and-hashish-users-in-the-usa-a-nhanes-based-cross-sectional-study
#15
JOURNAL ARTICLE
Mohammad Helmi, Abdulmalik Aldawood, Mohammed AlOtaibi, Essam Alnasser, Abdulrahman AlSubaie, Muath Aldosari
BACKGROUND: As of November 2023, twenty-four states, two territories, and DC have legalized marijuana for non-medical use, leading to concerns about its potential oral health effects. This study investigated the association between marijuana use and clinical dental outcomes among adults in the US. METHODS: We analyzed data from the National Health and Nutrition Examination Survey (NHANES) from 2015 to 2018 using a cross-sectional survey of non-institutionalized US civilians...
April 2024: Saudi Dental Journal
https://read.qxmd.com/read/38689986/patients-knowledge-about-the-uses-risks-and-beliefs-surrounding-the-regulation-and-safety-of-cannabis-sativa-l-in-peru
#16
JOURNAL ARTICLE
José F Ramírez-Méndez, Pedro Wong-Salgado, Peter Gámez, Pedro Solis, Jeel Moya-Salazar
In recent decades, there has been a significant rise in the utilization of medical cannabis. Understanding the various facets surrounding its usage and regulation is paramount for patients, health professionals, and policymakers. This cross-sectional study conducted at the CANNAVITAL clinic in Lima, Peru aimed to assess the basic knowledge, attitudes towards use, and beliefs regarding regulation and safety of Cannabis sativa L. Among 86 patients (mean age: 41 ± 7.8 years; 53.4% women) actively receiving medical cannabis treatment for at least one year, we utilized the 22-item KUC-22 questionnaire to evaluate their understanding of cannabis, risk factors, legislation, medical and recreational use...
April 15, 2024: Heliyon
https://read.qxmd.com/read/38687734/drug-use-and-covid-19-testing-vaccination-and-infection-among-underserved-minority-communities-in-miami-florida
#17
JOURNAL ARTICLE
Javier A Tamargo, Haley R Martin, Janet Diaz-Martinez, Ivan Delgado-Enciso, Angelique Johnson, Jose A Bastida Rodriguez, Mary Jo Trepka, David R Brown, Nana A Garba, Eneida O Roldan, Yolangel Hernandez Suarez, Aileen M Marty, Zoran Bursac, Adriana Campa, Marianna K Baum
The Coronavirus Disease 2019 (COVID-19) pandemic has disproportionately impacted people who use drugs (PWUD). This study explored relationships between drug use, COVID-19 testing, vaccination, and infection. This cross-sectional study was conducted in Miami, Florida between March 2021 and October 2022 as part of the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics-Underserved Populations (RADx-UP) initiative and the Miami Adult Studies on HIV (MASH) cohort. Users of cannabis, cocaine/crack, heroin/fentanyl, methamphetamines, hallucinogens, and/or prescription drug misuse in the previous 12 months were considered PWUD...
2024: PloS One
https://read.qxmd.com/read/38685622/polypharmacy-as-formal-training-and-a-model-of-practice
#18
JOURNAL ARTICLE
Michael J Schuh, Sheena K Crosby
Traditional definitions of polypharmacy may largely not account for the market proliferation of herbal and dietary supplements, cannabis products, or incorporate the new science of pharmacogenomics (PGx). Polypharmacy is encountered by most pharmacists providing patient care in many settings. The "polypharmacist" can assist patients and providers with solving medication-related problems (MRPs) in this new and challenging environment of supplements and cannabis products by utilizing traditional pharmacology and pharmacokinetic principles, including PGx, broadly across many medical disciplines...
May 1, 2024: Senior Care Pharmacist
https://read.qxmd.com/read/38683093/-topical-use-of-cannabis-in-inflammatory-diseases-in-patients-of-the-ips-salud-social-in-barranquilla-colombia
#19
JOURNAL ARTICLE
Juan Calderón, Carlos Parga-Lozano, Nohemí Santodomingo, Paola Gutiérrez, Fanny Lambraño
OBJECTIVE: To relate the topical use of cannabis as an analgesic therapeutic alternative in patients with some inflammatory diseases in Salud Social I.P.S during May to July 2023. METHODS: An analytical, retrospective study was carried out. The population from which the sample was obtained corresponds to patients diagnosed with Arthrosis, Unspecified, Non-Toxic Multinodular Goiter, Epilepsy, Unspecified Type Venous Insufficiency (Chronic) (Peripheral), Unspecified Lumbago, Secondary Gonarthrosis, Rotator Cuff Syndrome, Carpal Tunnel Syndrome, in Salud Social I...
February 1, 2024: Revista Alergia Mexico: Organo Oficial de la Sociedad Mexicana de Alergia e Inmunología, A.C
https://read.qxmd.com/read/38680212/cannabis-oil-extracts-for-chronic-pain-what-else-can-be-learned-from-another-structured-prospective-cohort
#20
JOURNAL ARTICLE
Dorit Pud, Suhail Aamar, Bareket Schiff-Keren, Roee Sheinfeld, Silviu Brill, Dror Robinson, Yaakov Fogelman, George Habib, Haggai Sharon, Howard Amital, Boris Boltyansky, Simon Haroutounian, Elon Eisenberg
INTRODUCTION: The use of medicinal cannabis for managing pain expands, although its efficacy and safety have not been fully established through randomized controlled trials. OBJECTIVES: This structured, prospective questionnaire-based cohort was aimed to assess long-term effectiveness and safety of cannabis oil extracts in patients with chronic pain. METHODS: Adult Israeli patients licensed to use cannabis oil extracts for chronic pain were followed prospectively for 6 months...
April 2024: Pain Reports
keyword
keyword
17304
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.